液体活检在前列腺癌诊治中的研究进展  

Research Progress of Liquid Biopsy in Diagnosis and Treatment of Prostate Cancer

作　　者：董振坤 张璐 陈辉[1] DONG Zhenkun;ZHANG Lu;CHEN Hui(Department of Urology,Harbin Medical University Cancer Hospital,Harbin 150081,China)

机构地区：[1]哈尔滨医科大学附属肿瘤医院泌尿外科,哈尔滨150081

出　　处：《医学综述》2022年第3期494-498,共5页Medical Recapitulate

基　　金：哈尔滨市科技创新人才研究专项(RC2017XK004066)。

摘　　要：液体活检作为肿瘤的无创诊断技术,近年来在前列腺癌的诊疗中取得了突破性进展。但基于实体肿瘤的生物标志物开发面临诸多挑战,特别是晚期前列腺癌常发生骨转移,很难评估骨转移潜在的基因异质性。与传统组织活检相比,液体活检具有取材方便、无创、患者依从性好、可实时监测等优点,可以进行连续检测,能够监测疾病的复发和随着时间推移对治疗的反应,在前列腺癌患者的早期诊断、预后评估和肿瘤监测中将发挥重要作用。未来基于液体活检标志物的精准识别和分析,将推动液体活检技术在临床的广泛应用。As a non-invasive diagnostic technique for tumors,liquid biopsy has made a breakthrough in the diagnosis and treatment of prostate cancer in recent years,while the development of biomarkers based on solid tumors faces many challenges.In particular,advanced prostate cancer often metastasizes to the bone,and it is difficult to assess the potential genetic heterogeneity of bone metastasis.Compared with traditional tissue biopsy,liquid biopsy has the advantages of convenient access to materials,non-invasiveness,good patient compliance,and real-time monitoring.The test can be continuously carried,and it can monitor the recurrence of the disease and the response to treatment over time.It will play an important role in the early diagnosis,prognostic evaluation and tumor monitoring of the patients with prostate cancer.In the future,the accurate identification and analysis of liquid biopsy markers will promote the wide clinical application of liquid biopsy technology.

关 键 词：前列腺癌 液体活检 循环肿瘤细胞 循环肿瘤DNA 细胞游离DNA 

分 类 号：R737.25[医药卫生—肿瘤]